SIGA Technologies
SIGA

$8.61

8.03%

Market Cap: $614M

About: SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.

Employees: 45

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

32% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 41

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

5% more funds holding

Funds holding: 144 [Q1] → 151 (+7) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

0.53% less ownership

Funds ownership: 48.06% [Q1] → 47.53% (-0.53%) [Q2]

12% less capital invested

Capital invested by funds: $293M [Q1] → $257M (-$36.5M) [Q2]

58% less call options, than puts

Call options by funds: $3.35M | Put options by funds: $7.99M

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for SIGA.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about SIGA published over the past 30 days

Zacks Investment Research

Siga Technologies Inc. (SIGA) Stock Drops Despite Market Gains: Important Facts to Note

In the latest trading session, Siga Technologies Inc. (SIGA) closed at $7.88, marking a -1.38% move from the previous day.

Siga Technologies Inc. (SIGA) Stock Drops Despite Market Gains: Important Facts to Note

Zacks Investment Research

Siga Technologies Inc. (SIGA) Stock Dips While Market Gains: Key Facts

In the most recent trading session, Siga Technologies Inc. (SIGA) closed at $7.51, indicating a -0.53% shift from the previous trading day.

Siga Technologies Inc. (SIGA) Stock Dips While Market Gains: Key Facts

SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract with the U.S. Department of Defense (DOD) for the procurement of approximately $9 million of TPOXX® (Contract number: W911SR24C0030). This award is comprised primarily of oral TPOXX®, with a small amount of intravenous (IV) TPOXX®, and represents the third procurement contract award from the DOD over the past three years.

SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®

Stock Of The Day: Bull Trap Snares SIGA Technologies On Heels Of Mpox Study

So-called “bull traps” often frustrate traders, as they did on Wednesday, snaring shares of SIGA Technologies Inc SIGA — and there may be another one today.

Stock Of The Day: Bull Trap Snares SIGA Technologies On Heels Of Mpox Study

SIGA Technologies: Poised For A Potential Windfall From Monkeypox Emergency Declaration

SIGA Technologies focuses on antiviral treatments, with its lead product TPOXX (tecovirimat) approved for smallpox and other orthopoxviruses. The PALM 007 study of tecovirimat in monkeypox patients failed to meet its primary endpoint but showed safety. SIGA's reliance on US government contracts, especially for TPOXX, introduces substantial revenue concentration risk.

SIGA Technologies: Poised For A Potential Windfall From Monkeypox Emergency Declaration

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

The World Health Organisation on Wednesday declared the upsurge of monkeypox virus or ‘Mpox' in Africa a public health emergency of international concern (PHEIC), stating it had the potential to spread across countries in Africa and possibly outside the continent.

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

Topline Results from PALM 007 Study of SIGA's Tecovirimat in Treatment of Mpox Released

NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced topline results from a preliminary analysis of the PALM 007 (Tecovirimat for Treatment of Monkeypox Virus) clinical trial (NCT05559099). NIAID reported that the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the Democratic Republic of the Congo (DRC) with monkeypox (mpox), who were administered SIGA's tecovirimat, a highly targeted antiviral treatment, versus placebo. All patients in this study were hospitalized for the entire duration of treatment. This study was not a registration study conducted under an U.S. FDA Investigational New Drug Application.

Topline Results from PALM 007 Study of SIGA's Tecovirimat in Treatment of Mpox Released

SIGA Technologies, Inc. (SIGA) Q2 2024 Earnings Call Transcript

SIGA Technologies, Inc. (NASDAQ:SIGA ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Diem Nguyen - Chief Executive Officer Daniel Luckshire - Chief Financial Officer Conference Call Participants Soo Romanoff - Edison Group Operator Welcome to SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

SIGA Technologies, Inc. (SIGA) Q2 2024 Earnings Call Transcript

SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 1, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results

Zacks Investment Research

Siga Technologies Inc. (SIGA) Ascends While Market Falls: Some Facts to Note

Siga Technologies Inc. (SIGA) reachead $9.72 at the closing of the latest trading day, reflecting a +0.83% change compared to its last close.

Siga Technologies Inc. (SIGA) Ascends While Market Falls: Some Facts to Note

See News Rankings